Clinical Trials · NCT06037252
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 414
- Start date
- Sep 2023
- Locations
- 40 sites, 4 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight